Tag Archive for: Investor

Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage

/in ,

Dan Mahony and Gareth Powell are long time, successful life sciences and healthcare investors. They are luminaries of the UK and European healthcare ecosystem, who have been investing since the late 1990s and initially worked together at Polar Capital where together they set up the biotech and healthcare investment funds. Gareth is still Head of […]

Read more

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

/in ,

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]

Read more

Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec

/in ,

We were privileged to hear visionary insights during Mike Ward’s fascinating fireside chat with Werner Lanthaler, CEO of Evotec. In the discussion, he asked Werner to share his views about the sector and big macro issues, as well as what it takes to build a biotech. This is what we learned: The teenage Werner wanted […]

Read more

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022

/in ,

Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]

Read more

Ariceum Therapeutics Q4 2022 Investor and Scientific Conference

/in

BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that its senior management team will be attending and hosting meetings at the following investor and scientific conferences in the fourth quarter of 2022. Read more…

Read more